Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
MEIP Stock Summary
In the News

All You Need to Know About MEI Pharma, Inc. (MEIP) Rating Upgrade to Strong Buy
MEI Pharma, Inc. (MEIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript
MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2023 Earnings Call Transcript September 26, 2023 5:00 PM ET Company Participants David Walsey - SVP, Corporate Affairs David Urso - President & CEO Jay File - CFO Richard Ghalie - CMO Conference Call Participants Yale Jen - Laidlaw & Company Stephen Willey - Stifel Operator Good day and welcome to the MEI Fiscal Year-End Earnings Call. My name is Gary and I will be the conference facilitator today.

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (“MEI”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate, announced today that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern.

MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $2.60. This compares to loss of $3.40 per share a year ago.

MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MEI Pharma, Inc. (MEIP) Q4 2022 Earnings Call Transcript
MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2022 Results Conference Call September 8, 2022 5:00 PM ET Company Participants David Walsey - Senior Vice President and Corporate Affairs Dan Gold - President and Chief Executive Officer Brian Drazba - Chief Financial Officer David Urso - Chief Operating Officer and General Counsel Richard Ghalie - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Robyn Karnauskas - Truist Yale Jen - Laidlaw & Co Nick Abbott - Wells Fargo Operator Good afternoon, and welcome to the MEI Pharma 2022 Fiscal Year End Conference Call. Please be advised that the call is being recorded at the Company's request.

Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List
Can these penny stocks continue to make gains The post Best Penny Stocks to Buy Right Now? 3 For Your Mid-June List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now
Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy?

MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MEIP Financial details
MEIP Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-06-30
Metric | History | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 4.41 | 6.35 | 7.42 | 7.47 | 7.33 | |
Net income per share | -15.09 | -10.1 | -14.69 | -10.04 | -4.78 | |
Operating cash flow per share | -26.4 | 7.52 | -9.29 | -8.94 | -7.88 | |
Free cash flow per share | -26.59 | 7.33 | -9.49 | -9.03 | -7.88 | |
Cash per share | 66.83 | 40.1 | 44.58 | 28.11 | 15.11 | |
Book value per share | 43 | 17.18 | 12.02 | 9.61 | 3.7 | |
Tangible book value per share | 42.77 | 17.18 | 12.02 | 9.61 | 3.7 | |
Share holders equity per share | 43 | 17.18 | 12.02 | 9.61 | 3.7 | |
Interest debt per share | -51.19 | 0 | 2.41 | 1.82 | 1.91 | |
Market cap | 56.18M | 376.16M | 196.19M | 66.51M | 43.84M | |
Enterprise value | 46.59M | 363.83M | 195.94M | 60.41M | 39.66M | |
P/E ratio | -3.34 | -8.17 | -3.88 | -1.22 | -1.38 | |
Price to sales ratio | 11.43 | 13.01 | 7.68 | 1.63 | 0.9 | |
POCF ratio | -1.91 | 10.98 | -6.14 | -1.36 | -0.84 | |
PFCF ratio | -1.9 | 11.27 | -6 | -1.35 | -0.83 | |
P/B Ratio | 1.17 | 4.81 | 4.74 | 1.27 | 1.78 | |
PTB ratio | 1.17 | 4.81 | 4.74 | 1.27 | 1.78 | |
EV to sales | 9.48 | 12.58 | 7.67 | 1.48 | 0.81 | |
Enterprise value over EBITDA | -0.63 | -233.07 | -2.24 | -0.63 | -1.04 | |
EV to operating cash flow | -1.58 | 10.62 | -6.13 | -1.24 | -0.76 | |
EV to free cash flow | -1.57 | 10.9 | -6 | -1.23 | -0.76 | |
Earnings yield | -0.3 | -0.12 | -0.26 | -0.82 | -0.73 | |
Free cash flow yield | -0.53 | 0.09 | -0.17 | -0.74 | -1.2 | |
Debt to equity | 0 | 0 | 0.2 | 0.18 | 0.52 | |
Debt to assets | 0 | 0 | 0.05 | 0.05 | 0.11 | |
Net debt to EBITDA | 0.13 | 7.9 | 0 | 0.06 | 0.11 | |
Current ratio | 5.75 | 8.95 | 5.44 | 6.84 | 5.29 | |
Interest coverage | 0.81 | 0 | 0 | -265.79 | 0 | |
Income quality | 1.75 | -0.74 | 0.63 | 0.9 | 1.65 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.97 | 0.58 | 0.96 | 0.75 | 0.68 | |
Research and developement to revenue | 6.57 | 1.18 | 2.72 | 2.1 | 1.07 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | -0.03 | 0.02 | 0.01 | 0 | |
Capex to revenue | -0.04 | -0.03 | -0.03 | -0.01 | 0 | |
Capex to depreciation | -2.71 | -8.2 | -2.48 | -1.47 | -0.09 | |
Stock based compensation to revenue | 1.34 | 0.24 | 0.4 | 0.21 | 0.07 | |
Graham number | 120.83 | 62.49 | 63.03 | 46.61 | 19.93 | |
ROIC | -0.96 | -0.31 | -1.2 | -1.06 | -0.62 | |
Return on tangible assets | -0.2 | -0.22 | -0.29 | -0.31 | -0.26 | |
Graham Net | 39.22 | 14.59 | 7.66 | 6.49 | 0.69 | |
Working capital | 67.9M | 185.34M | 134.52M | 142.68M | 87.19M | |
Tangible asset value | 47.67M | 78.22M | 41.36M | 52.41M | 24.62M | |
Net current asset value | 47.47M | 77.13M | 32.08M | 41.7M | 11.34M | |
Invested capital | 0 | 0 | 0.2 | 0.18 | 0.52 | |
Average receivables | 2.64M | 12.85M | 14M | 8.81M | 5.06M | |
Average payables | 4.22M | 3.61M | 4.4M | 7.14M | 7.03M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 391.66 | 257.78 | 108.38 | 90.08 | 0.64 | |
Days payables outstanding | 409.87 | 333.02 | 1.65K | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.93 | 1.42 | 3.37 | 4.05 | 574.31 | |
Payables turnover | 0.89 | 1.1 | 0.22 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.35 | -0.59 | -1.22 | -1.04 | -1.29 | |
Capex per share | -0.19 | -0.2 | -0.21 | -0.09 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q1
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.31 | 4.91 | 0.88 | 0.22 | 9.8 | |
Net income per share | -2.57 | 1.54 | -2.17 | -1.51 | 8.46 | |
Operating cash flow per share | -2.22 | -2.14 | -1.82 | -1.7 | -2.78 | |
Free cash flow per share | -2.23 | -2.14 | -1.82 | -1.69 | -2.77 | |
Cash per share | 20.77 | 18.64 | 16.81 | 15.11 | 12.34 | |
Book value per share | 5.6 | 7.26 | 5.16 | 3.7 | 12.21 | |
Tangible book value per share | 5.6 | 7.26 | 5.16 | 3.7 | 12.21 | |
Share holders equity per share | 5.6 | 7.26 | 5.16 | 3.7 | 12.21 | |
Interest debt per share | 2.13 | 2.08 | 1.82 | 1.91 | 1.86 | |
Market cap | 51.97M | 31.98M | 30.65M | 43.84M | 46.71M | |
Enterprise value | 51M | 34.44M | 34.89M | 39.66M | 55.72M | |
P/E ratio | -0.76 | 0.78 | -0.53 | -1.09 | 0.21 | |
Price to sales ratio | 5.95 | 0.98 | 5.2 | 30.09 | 0.72 | |
POCF ratio | -3.52 | -2.24 | -2.53 | -3.88 | -2.53 | |
PFCF ratio | -3.5 | -2.24 | -2.53 | -3.89 | -2.53 | |
P/B Ratio | 1.39 | 0.66 | 0.89 | 1.78 | 0.57 | |
PTB ratio | 1.39 | 0.66 | 0.89 | 1.78 | 0.57 | |
EV to sales | 5.84 | 1.05 | 5.92 | 27.22 | 0.85 | |
Enterprise value over EBITDA | -2.65 | 4.04 | -2.14 | -3.61 | 1.01 | |
EV to operating cash flow | -3.45 | -2.41 | -2.88 | -3.51 | -3.01 | |
EV to free cash flow | -3.44 | -2.41 | -2.88 | -3.52 | -3.01 | |
Earnings yield | -0.33 | 0.32 | -0.47 | -0.23 | 1.21 | |
Free cash flow yield | -0.29 | -0.45 | -0.4 | -0.26 | -0.4 | |
Debt to equity | 0.37 | 0.28 | 0.38 | 0.52 | 0.15 | |
Debt to assets | 0.08 | 0.09 | 0.1 | 0.11 | 0.12 | |
Net debt to EBITDA | 0.05 | 0.29 | -0.26 | 0.38 | 0.16 | |
Current ratio | 6.35 | 5.89 | 5.1 | 5.29 | 10.32 | |
Interest coverage | -37.96 | 18.37 | 17.2 | 852.31 | 0 | |
Income quality | 0.89 | -1.39 | 0.79 | 1.13 | -0.33 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.86 | 0.26 | 1.22 | 6.84 | 0.1 | |
Research and developement to revenue | 2.23 | 0.47 | 2.56 | 1.76 | 0.05 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.01 | 0 | 0 | 0.02 | 0 | |
Capex to depreciation | -0.64 | 0 | 0 | 0.29 | 0.08 | |
Stock based compensation to revenue | 0.18 | 0.02 | 0.16 | 0.21 | 0.01 | |
Graham number | 17.98 | 15.85 | 15.88 | 11.19 | 48.21 | |
ROIC | -0.29 | 0.14 | -0.25 | -0.2 | 0.53 | |
Return on tangible assets | -0.1 | 0.07 | -0.11 | -0.08 | 0.56 | |
Graham Net | 2.69 | 4.39 | 2.35 | 0.69 | 9.35 | |
Working capital | 125.47M | 110.79M | 96.86M | 87.19M | 79.86M | |
Tangible asset value | 37.31M | 48.37M | 34.35M | 24.62M | 81.36M | |
Net current asset value | 22.63M | 34.22M | 20.65M | 11.34M | 68.53M | |
Invested capital | 0.37 | 0.28 | 0.38 | 0.52 | 0.15 | |
Average receivables | 8.9M | 6.73M | 5.14M | 2.33M | 42.5K | |
Average payables | 8.17M | 6.24M | 4.23M | 5.26M | 4.68M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 79.98 | 15.68 | 69.94 | 5.25 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.13 | 5.74 | 1.29 | 17.14 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.46 | 0.21 | -0.42 | -0.41 | 0.69 | |
Capex per share | -0.01 | 0 | 0 | 0 | 0 |
MEIP Frequently Asked Questions
What is MEI Pharma, Inc. stock symbol ?
MEI Pharma, Inc. is a US stock , located in San diego of Ca and trading under the symbol MEIP
What is MEI Pharma, Inc. stock quote today ?
MEI Pharma, Inc. stock price is $6.72 today.
Is MEI Pharma, Inc. stock public?
Yes, MEI Pharma, Inc. is a publicly traded company.